Pennsylvania Bill Proposes Single Pharmacy Benefit Administrator to Lower Drug Costs

A bill introduced in the Pennsylvania House of Representatives would shift the management of prescription drug benefits for state employee health plans and Medicaid from multiple private pharmacy benefit managers to a single, state-appointed Pharmacy Benefit Administrator. According to testimony before the House Health Committee, the change aims to reduce drug costs, increase price transparency, and align financial incentives with patient health rather than PBM profits.

Key takeaways from the proposal

• House Bill 1799, sponsored by Representative Rob Matzie, would replace the current multi-PBM system with a single administrator selected through a competitive bidding process.
• Proponents claim the current model allows PBMs to inflate costs through hidden fees, spread pricing, and rebate arrangements that benefit PBMs but not patients or taxpayers.
• Opponents warn that a single administrator could reduce competition and limit plan flexibility, potentially leading to higher costs or fewer choices.
• The bill is part of a broader national push to reform PBM practices, with several states exploring similar single-administrator or transparency measures.

What the bill would do

The legislation would direct the state to select one entity to administer pharmacy benefits for the Pennsylvania Employees Benefit Trust Fund, the state Medicaid program, and other publicly funded health plans. The administrator would be required to operate under a transparent fee-for-service model, eliminating the practice of spread pricing, where PBMs charge plans more than they reimburse pharmacies and keep the difference.

The mechanics matter here. Rather than handing the job to a favored company, the bill calls for selecting the single administrator through a competitive bidding process, so firms would compete up front on the terms and fees they offer. Once chosen, that administrator would run the benefit for the major state programs, including the fund covering public employees and the state Medicaid program, under a fee-for-service arrangement. In plain terms, it would be paid a defined amount to do a defined job, rather than earning more when drug prices or volumes rise.

That distinction, being paid a flat fee versus profiting from the spread, is the entire philosophical core of the bill. Supporters argue it converts the administrator from a party that benefits when costs are murky into one whose only job is to run the benefit cleanly and cheaply. Everything else in the proposal, the transparency requirements and the ban on spread pricing, flows from that single change in how the middleman gets paid.

Under the current system, multiple PBMs negotiate separately with drug manufacturers and pharmacies, creating a complex web of rebates, discounts, and fees that often lack transparency. Supporters of the bill say this opacity makes it impossible for the state to know the true cost of medications and allows PBMs to profit at the expense of taxpayers and patients.

How did PBMs get so powerful?

PBMs did not set out to be villains, and understanding how they grew helps explain why reform is so contested. They began decades ago as straightforward claims processors, the back-office plumbing that handled the paperwork when someone filled a prescription. Over time they took on more: negotiating discounts, building formularies, running mail-order pharmacies, and managing entire drug benefits for insurers and employers.

Two forces turned that useful middleman role into a source of concern. The first was consolidation. Wave after wave of mergers left a few enormous players where there had once been many, concentrating pricing power. The second was integration with insurers. In recent years the largest PBMs became arms of the biggest health insurance companies, so the same corporate family could insure a patient, manage their drug benefit, and own the pharmacy that dispensed the pills. Each step was defensible on its own, but the cumulative result is a system so complex and interlinked that even the states writing the checks struggle to see where the money goes. That opacity, more than any single villainous act, is what bills like this one are reacting to.

How do PBMs actually make money?

To understand why a state would want to blow up its own drug-benefit setup, you have to see how pharmacy benefit managers earn revenue, because much of it is invisible to the patient at the counter. PBMs sit in the middle of the drug supply chain, between manufacturers, insurers, and pharmacies, and they profit from that position in several ways at once.

• Spread pricing. The PBM bills the health plan one price for a medication and reimburses the pharmacy a lower one, then keeps the difference. The plan often cannot see the gap, which is the core practice this bill targets by mandating a transparent, flat-fee model.
• Rebates. Drug manufacturers pay PBMs rebates in exchange for favorable placement on the formulary, the list of covered drugs. The concern is that a bigger rebate can win a spot even when a cheaper drug would cost the system less overall, because the rebate flows to the PBM rather than fully to the patient.
• Formulary control. By deciding which drugs are covered, preferred, or excluded, PBMs steer which products patients can realistically get, which gives them enormous leverage over manufacturers and pharmacies alike.
• Pharmacy fees. A web of fees charged to pharmacies, sometimes collected well after a prescription is filled, adds another revenue stream and is a frequent complaint from independent pharmacists.

The through-line is that a PBM’s income is often tied to the flow and list price of drugs rather than to getting patients the lowest net cost. That is the misalignment the Pennsylvania bill is trying to fix by paying a single administrator a fixed fee for its work, so its incentive is to administer efficiently rather than to profit from the spread.

Testimony and debate

The House Health Committee heard testimony from legislators, healthcare advocates, pharmacy representatives, and PBM industry officials. Representative Matzie argued that the current system is broken and that a single administrator could save the state tens of millions of dollars annually by simplifying negotiations and eliminating conflicts of interest.

Supporting witnesses pointed to examples from other states that have adopted similar models, such as West Virginia and Ohio, where officials reported measurable savings and improved transparency. However, critics noted that those transitions were not without challenges, including implementation delays and disputes over contract terms.

Opponents, including representatives from the PBM industry, contended that multiple PBMs create competitive pressure that keeps prices low. They argued that a single administrator would concentrate power and could lead to higher costs if the chosen entity fails to negotiate effectively or becomes subject to political influence.

Why the biggest PBMs draw so much scrutiny

Part of what fuels reform efforts is how concentrated this industry has become. By most estimates, the three largest PBMs together manage roughly 80 percent of prescription claims in the United States. When a handful of companies process the vast majority of the nation’s prescriptions, their internal pricing decisions ripple out to almost everyone, which is why state legislators and federal regulators alike have taken an interest.

The bigger structural concern is vertical integration. Each of the three dominant PBMs is now part of a larger healthcare conglomerate that also includes a major insurer and, in many cases, its own pharmacies. That means a single corporate parent can sit on multiple sides of the same transaction: it can own the insurer paying the claim, the PBM setting the price, and the pharmacy filling the prescription. Critics argue this makes it far harder to know whether the prices being charged reflect genuine competition or simply money moving between pockets of the same company.

Supporters of the industry counter that scale is exactly what gives PBMs the negotiating muscle to extract discounts from drug manufacturers, and that stripping that leverage away could backfire. This is the genuine tension at the heart of the Pennsylvania debate. A single state-appointed administrator trades the supposed benefits of private competition for the promise of transparency and aligned incentives. Whether that trade pays off depends heavily on how the contract is written and how well the state manages it.

What could go wrong with a single administrator?

A fair look at the proposal has to take the opponents’ warnings seriously, because a single administrator concentrates responsibility as much as it concentrates power. If the chosen entity negotiates poorly, or if the contract is written loosely, the state could end up locked into worse terms than a competitive market might have produced, with fewer easy off-ramps.

Execution risk is not hypothetical. Even supporters concede that the states held up as success stories hit real snags during the switch, including delays and disputes over contract terms. Moving millions of prescriptions onto a new administrator is a massive operational undertaking, and mistakes during the transition can mean denied claims or confusion at the pharmacy counter for ordinary patients. There is also the worry about political influence: when the government selects the administrator, the decision can become vulnerable to lobbying and favoritism in ways a private contract might not.

The honest read is that the single-administrator model is not automatically better or worse. It swaps one set of risks, opaque middlemen with misaligned incentives, for another, concentration and execution risk. Which set a state prefers, and how competently it manages the result, is what actually determines whether patients and taxpayers come out ahead.

National context

The Pennsylvania bill aligns with a broader trend of state-level PBM reform. Several states have enacted laws requiring PBMs to register, report pricing data, or disclose rebates. A handful have moved toward single-administrator models for public programs. Federal attention has also increased, with the Federal Trade Commission investigating PBM practices and Congress considering various reform bills.

The federal spotlight has intensified in particular. The Federal Trade Commission has been examining the practices of the largest PBMs and their effect on drug prices and independent pharmacies, and its scrutiny has given state-level efforts additional momentum. In Congress, various bipartisan proposals have circulated to require more disclosure, curb spread pricing in public programs, and delink PBM compensation from a drug’s list price. Progress at the federal level has been uneven, which is one reason states have not waited.

At the state level, the approaches vary in ambition. Many states have passed laws simply requiring PBMs to register, report pricing data, or disclose rebates. A smaller number have gone further toward the single-administrator or transparent pass-through models that Pennsylvania is now weighing. Some have experimented with reverse-auction approaches, in which bidders compete to offer the lowest transparent price to administer the benefit. The experiences cited in testimony, from states like Ohio and West Virginia, are exactly the kind of real-world evidence lawmakers lean on, though as critics noted, those transitions came with their own implementation headaches.

The push for reform comes amid rising prescription drug costs, which account for about 10 percent of national health spending. Critics argue that PBMs, who act as middlemen between insurers, drug manufacturers, and pharmacies, have an incentive to favor higher-priced drugs that generate larger rebates, rather than seeking the lowest net cost for patients.

What could this mean for patients and for expensive drugs?

For an individual covered by a state plan, the promised payoff of reform is not abstract. When a system pays closer to the true net cost of a drug, those savings can translate into lower premiums, lower copays, or at least a slower rise in both. Greater transparency also makes it easier to see when a covered drug is being favored for reasons that serve the middleman rather than the patient.

The stakes are highest for expensive medications, and few categories illustrate this better than the newer weight-loss and diabetes drugs. GLP-1 medications carry high list prices, and whether a patient can get one, and what they pay, often comes down to formulary decisions and rebate arrangements that PBMs control. When coverage is denied or the out-of-pocket cost is steep, patients are left navigating prior authorizations, step therapy, and confusing pricing. It is exactly this frustration that has pushed many people toward transparent, cash-pay alternatives outside the traditional insurance and PBM maze.

Picture a state employee prescribed a costly medication. Under the current tangle, she might face a surprise denial, a required trial of a cheaper drug first, or a copay that swings for reasons no one can clearly explain, because the true price is buried inside rebate and spread arrangements she never sees. Under a transparent, flat-fee administrator, the theory is that the plan pays closer to the real net price and the reasons behind a coverage decision are easier to trace. She may not notice the plumbing changing, but she would feel it in a steadier copay and fewer unexplained roadblocks. That, stripped of the policy jargon, is what proponents are actually promising.

That is the practical backdrop to a debate that can otherwise feel like distant policy. Whether you are waiting on a formulary decision or simply want to know what a medication or a lab panel actually costs without the markup, the appeal of flat, published pricing is easy to understand. Two options readers ask about most often, one for comprehensive lab testing and one for clinician-supervised GLP-1 and hormone care, both lean on that same transparent-pricing idea.

Frequently Asked Questions

What is a Pharmacy Benefit Administrator?

A Pharmacy Benefit Administrator, often called a pharmacy benefit manager or PBM, is a third-party company that manages prescription drug benefits for health plans. PBMs process claims, negotiate discounts with drug manufacturers, set pharmacy reimbursement rates, and create formularies. The proposed Pennsylvania model would replace multiple competing PBMs with a single government-designated administrator for state-funded programs.

How could a single administrator lower drug costs?

According to the bill’s supporters, a single administrator eliminates spread pricing and hidden rebates. The administrator would be paid a fixed fee rather than profiting from the difference between what it charges the state and what it pays pharmacies. This structure is intended to align the administrator’s incentives with obtaining the lowest possible net drug prices for the state and its beneficiaries. Proponents cite similar models in other states that have saved millions in public health spending.

What are the potential drawbacks of the single administrator model?

Critics argue that consolidating PBM services under one entity reduces competition, which could lead to higher administrative costs or less favorable contract terms. They also warn that a single administrator may have less flexibility to negotiate different formularies or plan designs for different populations. Some opponents fear that political pressures could influence contracting decisions, potentially introducing inefficiencies not present in a competitive private marketplace.

What is spread pricing?

Spread pricing is when a PBM charges a health plan more for a medication than it reimburses the pharmacy that dispensed it, and keeps the difference. The plan often cannot see the gap, so it does not know the true cost. The Pennsylvania bill would ban this practice for state programs by requiring a transparent flat-fee model instead.

How does this bill connect to the cost of drugs like GLP-1 medications?

PBMs decide which drugs a plan covers and on what terms, which directly shapes access to high-priced medications, including GLP-1 weight-loss and diabetes drugs. More transparent pricing and aligned incentives could, in theory, make coverage decisions clearer and reduce the hidden markups that drive up what plans and patients pay for these expensive drugs.

Would this bill affect my private insurance?

Not directly. As written, the proposal applies to state-funded plans such as coverage for public employees and Medicaid, not to private commercial insurance. Supporters hope a successful public-sector model would build pressure and provide a template for broader reform, but the bill itself is limited to programs the state controls.

This is an original report by Vital Signs Today, informed by reporting from Google News. Read the original source.

This article is for information only and is not medical advice. See our Medical Disclaimer.